MaxOvary

Non-invasive Solutions for PCOS

Health Tech & Life Sciences
Non Active, Dec 2024 ceased to operate

Company Overview

Snapshot

Founded in January 2023 by Eytan Frey, MaxOvary operates with 1–10 employees. The company secured its seed funding in January 2023 from Cactus Capital, marking a key early milestone in its development.

Business overview

MaxOvary is a Health Tech & Life Sciences company focused on developing non-invasive solutions for gynecological diseases, specifically targeting Polycystic Ovary Syndrome (PCOS). The company's core technology involves a transducer designed to enable innovative, breakthrough, and disposable treatment options. By addressing the physical and mental suffering associated with conventional treatments for women struggling with fertility, MaxOvary aims to provide more permanent solutions in the medical devices sector, serving the healthcare industry.

Company Intelligence Q&A

What is MaxOvary's primary focus?
MaxOvary is developing non-invasive solutions for gynecological diseases, particularly focusing on Polycystic Ovary Syndrome (PCOS).
When was MaxOvary founded?
MaxOvary was founded in January 2023.
Who are the founders of MaxOvary?
Eytan Frey is a co-founder and CEO of MaxOvary.
What type of technology does MaxOvary utilize?
MaxOvary is developing a transducer for innovative, breakthrough, disposable, and non-invasive treatment for gynecological diseases.
What is the current status of MaxOvary?
MaxOvary ceased to operate in December 2024.